1887

Abstract

Previous results in the laboratory of the authors showed that strain 905, isolated during ‘cachaça’ production, was able to colonize and survive in the gastrointestinal tract of germ-free and conventional mice, and to protect these animals against oral challenge with serotype Typhimurium or . In the present work, the effects of 905 on the translocation of . Typhimurium (mesenteric lymph nodes, Peyer's patches, spleen, liver) as well as on the immune system (number of Küpffer cells, immunoglobulin production, clearance of B) were evaluated in gnotobiotic and/or conventional mice. The treatment with the yeast reduced significantly the translocation of . Typhimurium to liver in gnotobiotic animals and to all the organs tested in conventional mice. The number of Küpffer cells per 100 hepatocytes in liver was significantly higher (<0.05) in yeast mono-associated mice (52.9±15.7) than in germ-free controls (38.1±9.0). Probably as a consequence, clearance of B from the bloodstream was more efficient in yeast mono-associated animals when compared to germ-free mice. Higher levels (<0.05) of secretory IgA in intestinal content and of IgA and IgM in serum were observed in yeast mono-associated mice when compared to germ-free group. Concluding, the protection against pathogenic bacteria observed in a previous study was probably due to a modulation of both local and systemic immunity of mice treated with 905.

Keyword(s): sIgA, secretory IgA
Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.46525-0
2007-03-01
2020-01-23
Loading full text...

Full text loading...

/deliver/fulltext/jmm/56/3/352.html?itemId=/content/journal/jmm/10.1099/jmm.0.46525-0&mimeType=html&fmt=ahah

References

  1. Bartlett, J. G. ( 1992; ). Antibiotic-associated diarrhea. Clin Infect Dis 15, 573–581.[CrossRef]
    [Google Scholar]
  2. Berg, R. D. ( 1995; ). Bacterial translocation from the gastrointestinal tract. Trends Microbiol 3, 149–154.[CrossRef]
    [Google Scholar]
  3. Berg, R. D. ( 1996; ). The indigenous gastrointestinal microflora. Trends Microbiol 4, 430–435.[CrossRef]
    [Google Scholar]
  4. Born, P., Lersch, C., Zimmerhackl, B. & Claassen, M. ( 1993; ). The Saccharomyces boulardii therapy of HIV-associated diarrhea. Dtsch Med Wochenschr 118, 765.
    [Google Scholar]
  5. Brandão, R. L., Castro, I. M., Bambirra, E. A., Amaral, S. C., Fietto, L. G., Tropia, M. J. M., Neves, M. J., Dos Santos, R. G., Gomes, N. C. M. & Nicoli, J. R. ( 1998; ). Intracellular signal triggered by cholera toxin in Saccharomyces boulardii and Saccharomyces cerevisiae. Appl Environ Microbiol 64, 564–568.
    [Google Scholar]
  6. Buts, J. P., Bernasconi, P., Vaerman, J. P. & Dive, C. ( 1990; ). Stimulation of secretory IgA and secretory component of immunoglobulins in small intestine of rats treated with Saccharomyces boulardii. Dig Dis Sci 35, 251–256.[CrossRef]
    [Google Scholar]
  7. Castagliuolo, I., Riegler, M. F., Valenick, L., Lamont, J. T. & Pothoulakis, C. ( 1999; ). Saccharomyces boulardii protease inhibits the effects of Clostridium difficile toxins A and B in human colonic mucosa. Infect Immun 67, 302–307.
    [Google Scholar]
  8. Chiva, M., Soriano, G., Rochat, I., Peralta, C., Rochat, F., Llovet, T., Mirelis, B., Schiffrin, E. J., Guarner, C. & Balanzo, J. ( 2002; ). Effect of Lactobacillus johnsonii La1 and antioxidants on intestinal flora and bacterial translocation in rats with experimental cirrhosis. J Hepatol 37, 456–462.[CrossRef]
    [Google Scholar]
  9. Ciriello, C. J. & Lachance, M. A. ( 2001; ). yeastcompare. University of Western Ontario, London, ON, Canada.
  10. Czerucka, D. & Rampal, P. ( 2002; ). Experimental effects of Saccharomyces boulardii on diarrheal pathogens. Microbes Infect 4, 733–739.[CrossRef]
    [Google Scholar]
  11. Czerucka, D., Roux, I. & Rampal, P. ( 1994; ). Saccharomyces boulardii inhibits secretagogue-mediated adenosine 3′,5′-cyclic monophosphate induction in intestinal cells. Gastroenterology 106, 65–72.
    [Google Scholar]
  12. Czerucka, D., Dahan, S., Mograbi, B., Rossi, B. & Rampal, P. ( 2000; ). Saccharomyces boulardii preserves the barrier function and modulates the transduction pathway induced in enteropathogenic Escherichia coli-infected T84 cells. Infect Immun 68, 5998–6004.[CrossRef]
    [Google Scholar]
  13. Dahan, S., Dalmasso, G., Imbert, V., Peyron, J.-F., Rampal, P. & Czerucka, D. ( 2003; ). Saccharomyces boulardii interferes with enterohemorrhagic Escherichia coli-induced signaling pathways in T84 cells. Infect Immun 71, 766–773.[CrossRef]
    [Google Scholar]
  14. Elmer, G. W., McFarland, L. V., Surawicz, C. M., Danko, L. & Greenberg, R. N. ( 1999; ). Behaviour of Saccharomyces boulardii in recurrent Clostridium difficile disease patients. Aliment Pharmacol Ther 13, 1663–1668.[CrossRef]
    [Google Scholar]
  15. Fietto, J. L. R., Araújo, R. S., Valadão, F. N., Fietto, L. G., Brandão, R. L., Neves, M. J., Gomes, C. O., Nicoli, J. R. & Castro, I. M. ( 2004; ). Molecular and physiological comparisons between Saccharomyces cerevisiae and Saccharomyces boulardii. Can J Microbiol 50, 615–621.[CrossRef]
    [Google Scholar]
  16. Food and Agriculture Organization of the United Nations & World Health Organization ( 2002; ). Guidelines for the Evaluation of Probiotics in Food, Food and Agriculture Organization of the United Nations and World Health Organization Working Group Report, London, Ontario, Canada, April 30–May 1 2002.
  17. Gregory, S. H., Sagnimeni, A. J. & Wing, E. J. ( 1996; ). Bacteria in the bloodstream are trapped in the liver and killed by immigrating neutrophils. J Immunol 157, 2514–2520.
    [Google Scholar]
  18. Gedek, B. R. ( 1999; ). Adherence of Escherichia coli serogroup O157 and the Salmonella typhimurium mutant DT 104 to the surface of Saccharomyces boulardii. Mycoses 42, 261–264.[CrossRef]
    [Google Scholar]
  19. Gun, F., Salman, T., Gurler, N. & Olgac, V. ( 2005; ). Effect of probiotic supplementation on bacterial translocation in thermal injury. Surg Today 35, 760–764.[CrossRef]
    [Google Scholar]
  20. Hajishengallis, G., Nikolova, E. & Russel, M. W. ( 1992; ). Inhibition of Streptococcus mutans adherence to saliva-coated hydroxyapatite by human secretory immunoglobulin A antibodies to the cell surface protein antigen I/II: reversal by IgA 1 protease cleavage. Infect Immun 60, 5057–5064.
    [Google Scholar]
  21. Hamuro, J., Akiyama, Y., Iguchi, Y., Isawa, M. & Matsuo, T. ( 1982; ). Distinct roles of serum factors induced by a T cell specific immune adjuvant lentinan in cellular immune responses. Int J Immunopharmacol 4, 268.
    [Google Scholar]
  22. Herek, O., Kara, I. G. & Kaleli, I. ( 2004; ). Effects of antibiotics and Saccharomyces boulardii on bacterial translocation in burn injury. Surg Today 34, 256–260.[CrossRef]
    [Google Scholar]
  23. Hirakata, Y., Tomono, K., Tateda, K., Matsumoto, T., Furuya, N., Shimoguchi, K., Kaku, M. & Yamaguchi, K. ( 1991; ). Role of bacterial association with Küpffer cells in occurrence of endogenous systemic bacteremia. Infect Immun 59, 289–294.
    [Google Scholar]
  24. Jahn, H. U., Ullrich, R., Schneider, T., Liehr, R. M., Schieferdecker, H. L., Holst, H. & Zeitz, M. ( 1996; ). Immunological and trophical effects of Saccharomyces boulardii on the small intestine in healthy human volunteers. Digestion 57, 95–104.[CrossRef]
    [Google Scholar]
  25. Jones, B. D. & Falkow, S. ( 1996; ). Salmonellosis: host immune responses and bacterial virulence determinants. Annu Rev Immunol 14, 533–561.[CrossRef]
    [Google Scholar]
  26. Kovacs, D. J. & Berk, T. ( 2000; ). Recurrent Clostridium difficile-associated diarrhea and colitis treated with Saccharomyces cerevisiae (baker's yeast) in combination with antibiotic therapy: a case report. J Am Board Farm Pract 13, 138–140.[CrossRef]
    [Google Scholar]
  27. Kumura, H., Tanoue, Y., Tsukahara, M., Tanaka, T. & Shimazaki, K. ( 2004; ). Screening of dairy yeast strains for probiotic applications. J Dairy Sci 87, 4050–4056.[CrossRef]
    [Google Scholar]
  28. Martins, F. S., Nardi, R. M. D., Arantes, R. M. E., Rosa, C. A., Neves, M. J. & Nicoli, J. R. ( 2005; ). Screening of yeast as probiotic based on capacities to colonize the gastrointestinal tract and to protect against enteropathogen challenge in mice. J Gen Appl Microbiol 51, 83–92.[CrossRef]
    [Google Scholar]
  29. McFarland, L. V. & Bernasconi, P. ( 1993; ). Saccharomyces boulardii: a review of an innovative biotherapeutic agent. Microb Ecol Health Dis 6, 157–171.[CrossRef]
    [Google Scholar]
  30. McFarland, L. V., Surawicz, C. M., Greenberg, R. N., Elmer, G. W., Moyer, K. A., Melcher, S. A., Bowen, K. E. & Cox, J. L. ( 1995; ). Prevention of β-lactam-associated diarrhea by Saccharomyces boulardii compared with placebo. Am J Gastroenterol 90, 439–448.
    [Google Scholar]
  31. Moreau, M. C., Raibaud, P. & Muller, M. C. ( 1982; ). Relation entre le développement du systéme immunitaire intestinal à IgA et l'établissement de la flore microbienne dans le tube digestif de souris holoxênique. Ann Inst Pasteur Immunol 133B, 29–39.
    [Google Scholar]
  32. Moura, L. N., Neumann, E., Vieira, L. Q. & Nicoli, J. R. ( 2001; ). Protection by Lactobacillus acidophilus UFV-H2B20 against experimental oral infection with Salmonella enterica subsp. enterica ser. Typhimurium in gnotobiotic and conventional mice. Br J Microbiol 32, 66–69.[CrossRef]
    [Google Scholar]
  33. National Research Council ( 1996; ). Guide for the Care and Use of Laboratory Animals. Washington, DC: National Academy Press.
  34. Neumann, E., Oliveira, M. A. P., Cabral, C. M., Moura, L. N., Nicoli, J. R., Vieira, E. C., Cara, D. C., Podoprigora, G. I. & Vieira, L. Q. ( 1998; ). Monoassociation with Lactobacillus acidophilus UFV-H2B20 stimulates the phagocytic system of germ-free mice. Br J Med Biol Res 31, 1565–1573.[CrossRef]
    [Google Scholar]
  35. Neves, M. J., Etchebehere, L., Brandão, R. L., Castro, I. M., Lima, M. E. & Nicoli, J. R. ( 2002; ). Partial characterization of cholera toxin binding on membranes of Saccharomyces boulardii. Microecol Ther 29, 185–190.
    [Google Scholar]
  36. Patchen, M. & McVittie, T. ( 1982; ). Effects of a soluble glucan on hemopoietic stem cell proliferation. Int J Immunopharmacol 4, 273.
    [Google Scholar]
  37. Pleasants, J. R. ( 1974; ). Gnotobiotics. In Handbook of Laboratory Animal Science, p. 119–174. Edited by E. C. Melby Jr & N. H. Altmann. Cleveland: CRC Press.
  38. Peret, L. A., Penna, F. J., Bambirra, E. A. & Nicoli, J. R. ( 1998; ). Dose effect of oral Saccharomyces boulardii treatments on morbidity and mortality in immunosuppressed mice. J Med Microbiol 47, 111–116.[CrossRef]
    [Google Scholar]
  39. Pothoulakis, C., Kelly, C. P., Joshi, M. A., Gao, N., O'Keane, C. J., Castagliuolo, I. & Lamont, J. T. ( 1993; ). Saccharomyces boulardii inhibits Clostridium difficile toxin A binding and enterotoxicity in rat ileum. Gastroenterology 104, 1108–1115.
    [Google Scholar]
  40. Qamar, A., Aboudola, S., Warny, M., Michetti, P., Pothoulakis, C., Lamont, J. T. & Kelly, C. P. ( 2001; ). Saccharomyces boulardii stimulates intestinal immunoglobulin A immune response to Clostridium difficile toxin A in mice. Infect Immun 69, 2762–2765.[CrossRef]
    [Google Scholar]
  41. Rodrigues, A. C., Nardi, R. M., Bambirra, E. A., Vieira, E. C. & Nicoli, J. R. ( 1996; ). Effect of Saccharomyces boulardii against experimental oral infection with Salmonella typhimurium and Shigella flexneri in conventional and gnotobiotic mice. J Appl Bacteriol 81, 251–256.[CrossRef]
    [Google Scholar]
  42. Rodrigues, A. C., Cara, D. C., Fretez, S. H. G. G., Cunha, F. Q., Vieira, E. C., Nicoli, J. R. & Vieira, L. Q. ( 2000; ). Saccharomyces boulardii stimulates sIgA production and the phagocytic system of gnotobiotic mice. J Appl Microbiol 89, 404–414.[CrossRef]
    [Google Scholar]
  43. Saba, T. M. ( 1970; ). Physiology and physiopathology of the reticuloendothelial system. Arch Intern Med 126, 1031–1052.[CrossRef]
    [Google Scholar]
  44. Scarpignato, C. & Rampal, P. ( 1995; ). Prevention and treatment of traveler's diarrhea: a clinical pharmacological approach. Chemotherapy 41, 48–81.[CrossRef]
    [Google Scholar]
  45. Silva, A. M., Barbosa, F. H. F., Duarte, R., Vieira, L. Q., Arantes, R. M. E. & Nicoli, J. R. ( 2004; ). Effect of Bifidobacterium longum ingestion on experimental salmonellosis in mice. J Appl Microbiol 97, 29–37.[CrossRef]
    [Google Scholar]
  46. Surawicz, C. M. ( 2003; ). Probiotics, antibiotic-associated diarrhoea and Clostridium difficile diarrhoea in humans. Best Pract Res Clin Gastroenterol 17, 775–783.[CrossRef]
    [Google Scholar]
  47. Surawicz, C. M., McFarland, L. V., Greenberg, R. N., Rubin, M., Fekety, R., Mulligan, M. E., Garcia, R. J., Brandmarker, S., Bowen, K. & other authors ( 2000; ). The search for a better treatment for recurrent Clostridium difficile disease: use of high-dose vancomycin combined with Saccharomyces boulardii. Clin Infect Dis 31, 1012–1017.[CrossRef]
    [Google Scholar]
  48. Van der Aa Kühle, A., Skovgaard, K. & Jespersen, L. ( 2005; ). In vitro screening of probiotic properties of Saccharomyces cerevisiae var. boulardii and food-borne Saccharomyces cerevisiae strains. Int J Food Microbiol 101, 29–39.[CrossRef]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.46525-0
Loading
/content/journal/jmm/10.1099/jmm.0.46525-0
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error